Managing Director, John Kelly speaks to Proactive about the broad applications for Atomo’s rapid blood-based tests at the ASX Small and Mid-Cap Conference. [embed]https://www.youtube.com/watch?v=wl4xxnxZ198[/embed]...
Atomo is mentioned in this Stockhead article as one of the Aussie companies involved in the efforts against COVID-19. Read the full article > ...
An article by Stockhead talks about our FY20 results and our COVID-19 antibody tests. Read the full article > ...
Medical diagnostics company Atomo Diagnostics (AT1) has seen its revenue jump nearly 900 per cent over FY20 as demand for COVID-19 antibody tests skyrockets. Read the full article > ...
An interview with Atomo MD, John Kelly on our FY20 results and strong uplift in revenues. Watch the full interview > ...
Atomo Diagnostics (ASX: AT1) has announced that the TGA has approved its rapid SARS-CoV-2 antibody blood test for use by medical professionals in Australia. Read the full article > ...
The healthcare community and broader market initially misunderstood the role of Atomo Diagnostic's COVID-19 antibody test, with CEO John Kelly saying it is designed to be used in conjunction with the gold-standard molecular polymerase chain reaction (PCR) swabs, not as a replacement. Read the full article >...
MD and CEO discusses TGA approval for our COVID-19 antibody test in this video interview. Read the full article > ...
As the state of Victoria in Australia records its deadliest day since the COVID-19 pandemic began, reporting 17 deaths and 394 new cases, Atomo Diagnostics Ltd.’s new COVID-19 antibody test could ease pressure on health care systems. Read the full article >...
In this interview, CEO John Kelly talks about how COVID-19 antibody testing will be important to verify any future vaccine for the virus. Watch the interview > ...
An article in BioSpectrum Asia on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
In this Stockhead article, CEO, John Kelly discusses why COVID-19 testing will continue for years not months, the development of a vaccine and how Atomo is focused on growing its non-COVID related businesses. Read the full article > ...
An article in BioSpace on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
This article in Small Caps article talks about the agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
22 July 2020 – Atomo Diagnostics Limited (ASX:AT1) is pleased to announce that Managing Director and CEO, John Kelly will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at 11.00 am AEST. Mr Kelly will provide an update on the recent developments...
Atomo CEO, John Kelly talks about the need for a greater focus on converting healthcare research into commercial outcomes in this Australian Financial Review article. Read the full article > ...
Atomo CEO, John Kelly talks about why Atomo developed a rapid diagnostic test for COVID-19. Read the full article > ...
Atomo is featured in this AFR article on the contraction in Australian IPO activity in 2020. Read the full article > ...
Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
Managing Director and CEO, John Kelly talks to Ausbiz about Atomo’s expanded partnership with NG Biotech and securing exclusive rights to market and distribute the COVID-19 antibody test for Australia, NZ and parts of SE Asia. Watch the interview here > ...
Stockhead’s Tim Boreham discusses Atomo’s background and history and the benefits of its rapid blood test devices for a range of conditions including COVID-19. Read the full article > ...
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
Lawyers Weekly discusses Atomo Diagnostics’ $30 million IPO and ASX listing as well its integrated rapid diagnostic test (RDT) devices. Read the full article >...
Atomo CEO, John Kelly was interviewed by Peter Switzer on Switzer TV, talking about what makes Atomo’s devices unique, how they can be used to test for COVID-19 and the company’s upcoming key milestones. [embed]https://www.youtube.com/watch?v=XpLiQ6Ujq0c[/embed]...
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
CEO John Kelly speaks to David Koch of Ausbiz about the Atomo’s successful ASX listing and support from blue-chip investors. [embed]https://assets.ausbiz.live/assets/e5a23332-74f7-432d-8e99-23fa1907814b/MP4/vimondio_video_1280x720_2000.mp4[/embed]...
An article by Damon Kitney in The Australian discusses how Atomo sharesclosed on their first day of trading on the Australian Securities Exchange at almost double their issue price as investors backed the rollout of its COVID-19 rapid testing equipment. Read the full article > ...
A feature in Biotech Daily talks about Atomo’s successful listing and the strong interest in the use of its integrated rapid test device for the testing of COVID-19 antibodies. Read the full article > ...